29, 30 In addition, Ibrutinib supplier the therapeutic agent, dosing protocol, patient characteristic, and study endpoint also varied remarkably across these trials. Therefore, conventional interferon cannot

be accepted as the standard care following HCC resection in CHC patients,7 despite a positive result from meta-analyses.31 Peg-interferon alpha plus ribavirin has become the standard anti-HCV regimen for a decade,32, 33 but its efficacy in preventing recurrence of curatively treated HCC remains undetermined. Two previous studies addressing this issue did not find peg-interferon-based therapy was associated with fewer recurrences.34, 35 In a cohort study consisting of 182 patients predominantly receiving radiofrequency ablation, Hagihara et al.34 reported HCC recurred similarly between 37 treated and 145 untreated patients (58% versus 70% at 5 years; P = 0.17). By taking a propensity score approach, Tanimoto et al.35 showed that recurrence did not differ between patients with and without postoperative peg-interferon-based Silmitasertib supplier treatment (55.3% versus 44.7%; P = 0.36; n = 38 in both groups). Both studies were probably underpowered because of the small number of participants. Besides, differences in demographics, HCC treatment, antiviral medication, outcome definition, and follow-up duration might also be factors in the discrepancy

between their results and ours. Based on our data, it needs a large sample comprising

representative subgroups to uncover the association between postoperative antiviral treatment and HCC recurrence, in that the recurrence rate among treated patients may be lower but remain substantial and that certain patient characteristics can modify the association. Peg-interferon plus ribavirin is highly effective in achieving HCV eradication in Taiwan,36, 37 where a favorable genetic variation in IL28B is this website prevalent,38 and has been validated among Taiwanese patients with HCC in a multicenter trial.39 However, this study in and of itself could not show how virological response might have influenced the association. Because linking the NHIRD to individual patients’ laboratory results was forbidden for privacy protection, we were unable to determine whether viral elimination mediated this association. Nevertheless, a large body of evidence has indicated that sustained virological response to antiviral treatment appears essential to reduce risk of developing HCV-related HCC.15, 16 The large-scale randomized and placebo-controlled HALT-C trial also refuted the antitumor efficacy of peg-interferon in CHC patients who failed to eradicate HCV.40 In our opinion, antiviral efficacy was more likely than an antiproliferative property to account for the observed association in this study, although further research is clearly required to clarify the underlying mechanism.